المؤلفون: Harsha Sri, Kamma, Ravisankar, Panchumarthy, Kumar Konidala, Sathish, Srinivasa Babu, P

المصدر: J Chromatogr B Analyt Technol Biomed Life Sci ; ISSN:1873-376X ; Volume:1241

مصطلحات موضوعية: Adagrasib, Bio-analytical method, LC-MS/MS, Pembrolizumab, Pharmacokinetic study

العلاقة: https://doi.org/10.1016/j.jchromb.2024.124171Test; https://pubmed.ncbi.nlm.nih.gov/38843708Test

الإتاحة: https://doi.org/10.1016/j.jchromb.2024.124171Test
https://pubmed.ncbi.nlm.nih.gov/38843708Test

المصدر: A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05609578Test

المصدر: A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04613596Test

المؤلفون: Revolution Medicines, Inc., Mirati Therapeutics Inc.

المصدر: A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Other Agents in Participants With Advanced Malignancies

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04418661Test

المصدر: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03785249Test